CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-03-21): EU follows U.S. with Tysabri liver warning

Regulatory

EU follows U.S. with Tysabri liver warning

Last Updated: 2008-03-21 9:45:13 -0400 (Reuters Health)

LONDON (Reuters) - The European Medicines Agency said on Thursday that warnings about liver injury should be added to the product information for Biogen Idec Inc and Elan Corp Plc's multiple sclerosis drug Tysabri.

The move follows a similar move by the U.S. Food and Drug Administration earlier this year.

The European watchdog said doctors should monitor the liver function of patients receiving Tysabri and patients who observe any signs of liver injury should see their doctor.

Tysabri has been haunted by safety concerns since it was approved.

Sales of the drug were suspended in 2005 amid three cases of progressive multifocal leukoencephalopathy, or PML. The drug returned to the market in 2006 with limits after the FDA decided that MS patients were willing to accept the risks in light of possible benefits.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.